Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Neuronetics Inc's Business Segments
Neuronetics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
2
Largest Segment
Clinical Services Segment
Total Revenue
$ 34
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Clinical Services Segment63%
- Medical Device Segment37.8%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Clinical Services Segment | $ 22 | 63% |
| Medical Device Segment | $ 13 | 37.8% |
Revenue by Product & Service Category - Q1 FY2026
- Clinic Revenue63%
- Service63%
- Product37.8%
- Treatment Sessions26.7%
- Neuro Star Advanced Therapy System9.4%
- Product and Service Other1.1%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Clinic Revenue | $ 22 | 63% |
| Service | $ 22 | 63% |
| Product | $ 13 | 37.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Neuronetics Inc dataset.
Description of Neuronetics Inc
Neuronetics Inc is a medical technology company that specializes in the development and manufacturing of non-invasive neuromodulation systems for the treatment of psychiatric and neurological disorders. The company's flagship product is NeuroStar Advanced Therapy, which is the first and only FDA-cleared transcranial magnetic stimulation (TMS) system for the treatment of major depressive disorder (MDD).
NeuroStar Advanced Therapy uses TMS to deliver magnetic pulses to specific areas of the brain associated with depression. The pulses stimulate the neurons in the brain, promoting the release of neurotransmitters and restoring normal brain activity. This non-invasive treatment option offers an alternative to traditional medications and electroconvulsive therapy (ECT) for patients suffering from MDD.
The NeuroStar system consists of a treatment coil, a stimulation unit, and a patient chair. The treatment coil is positioned on the patient's head, and the stimulation unit delivers targeted magnetic pulses to the brain. The patient sits comfortably in the chair during the treatment sessions, which typically last around 20-30 minutes and are conducted over a course of several weeks.
Neuronetics Inc has conducted extensive clinical trials to demonstrate the safety and efficacy of the NeuroStar system. The results have shown significant improvement in depressive symptoms, with many patients experiencing remission from their MDD. The treatment has a low side effect profile and does not require anesthesia or sedation, making it well-tolerated by patients.
In addition to MDD, Neuronetics Inc is exploring the potential of TMS therapy for other psychiatric and neurological conditions, such as anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and chronic pain. The company is actively involved in research and development to further advance the technology and expand its applications.
Neuronetics Inc is committed to providing comprehensive support to healthcare providers and patients. They offer training programs for clinicians on how to use the NeuroStar system effectively and provide ongoing technical support. They also have patient access programs to help individuals navigate insurance coverage and financial assistance options.
Overall, Neuronetics Inc is a pioneering company in the field of neuromodulation, revolutionizing the way depression and other psychiatric disorders are treated. Through their innovative technology and commitment to patient care, they are making a significant impact on the lives of individuals struggling with these debilitating conditions.
NeuroStar Advanced Therapy uses TMS to deliver magnetic pulses to specific areas of the brain associated with depression. The pulses stimulate the neurons in the brain, promoting the release of neurotransmitters and restoring normal brain activity. This non-invasive treatment option offers an alternative to traditional medications and electroconvulsive therapy (ECT) for patients suffering from MDD.
The NeuroStar system consists of a treatment coil, a stimulation unit, and a patient chair. The treatment coil is positioned on the patient's head, and the stimulation unit delivers targeted magnetic pulses to the brain. The patient sits comfortably in the chair during the treatment sessions, which typically last around 20-30 minutes and are conducted over a course of several weeks.
Neuronetics Inc has conducted extensive clinical trials to demonstrate the safety and efficacy of the NeuroStar system. The results have shown significant improvement in depressive symptoms, with many patients experiencing remission from their MDD. The treatment has a low side effect profile and does not require anesthesia or sedation, making it well-tolerated by patients.
In addition to MDD, Neuronetics Inc is exploring the potential of TMS therapy for other psychiatric and neurological conditions, such as anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and chronic pain. The company is actively involved in research and development to further advance the technology and expand its applications.
Neuronetics Inc is committed to providing comprehensive support to healthcare providers and patients. They offer training programs for clinicians on how to use the NeuroStar system effectively and provide ongoing technical support. They also have patient access programs to help individuals navigate insurance coverage and financial assistance options.
Overall, Neuronetics Inc is a pioneering company in the field of neuromodulation, revolutionizing the way depression and other psychiatric disorders are treated. Through their innovative technology and commitment to patient care, they are making a significant impact on the lives of individuals struggling with these debilitating conditions.
Neuronetics Inc. specializes in the development of innovative technologies for the treatment of neurological and psychiatric conditions, primarily focusing on Depression and other mood disorders. Their flagship product utilizes Transcranial Magnetic Stimulation (TMS) technology, specifically designed to provide non-invasive treatment options for patients suffering from various mental health issues. Below is a detailed breakdown of the segments, products, and services offered by Neuronetics:
1. Segments
Neuronetics primarily operates in the following segments:
- Healthcare Providers: This includes hospitals, outpatient clinics, and mental health facilities that utilize Neuronetics technologies to treat patients with depression and other mood disorders.
- Patients: Individuals suffering from Major Depressive Disorder (MDD) and other related conditions who seek alternative treatment options often overlooked or inadequately addressed by traditional therapies.
- Research Institutions: Collaborates with academic and clinical research organizations to explore new applications of TMS and contribute to the body of scientific knowledge regarding neurological treatments.
Products
Neuronetics’ product lineup is centered around its TMS therapy systems. The most prominent products include:
a. NeuroStar TMS Therapy System
- Overview: This is the flagship product and the first FDA-cleared TMS system for the treatment of MDD in adults who have failed to respond to previous antidepressant medications.
- Technology: Employs magnetic fields to stimulate nerve cells in the brain, which is believed to help improve symptoms of depression.
- Features:
- Non-invasive and well-tolerated with favorable side effect profiles compared to traditional medications.
- Offers a personalized treatment protocol tailored to each patient’s specific needs.
- Provides real-time data for monitoring treatment progress and outcomes.
Services
In addition to its products, Neuronetics offers several services aimed at facilitating the adoption and effective use of its TMS technology:
a. Training and Education
- Provider Training: Comprehensive training programs for healthcare providers on operating the NeuroStar system and delivering TMS therapy safely and effectively.
- Patient Education: Resources and support for patients to better understand TMS therapy, including its benefits, process, and potential outcomes.
b. Clinical Support
- Consultative Services: Offering expertise and guidance to healthcare facilities on how to integrate TMS therapy into their existing treatment protocols.
- Clinical Data Collection: Support in gathering and analyzing clinical outcomes data to enhance treatment effectiveness and establish best practices in the deployment of TMS therapy.
c. Patient Support
- Access Programs: Resources for patients to understand insurance coverage and financial assistance options for those in need of TMS therapy.
- Follow-Up Care: Continuous engagement with patients post-treatment to assess ongoing mental health and satisfaction with TMS therapy.
d. Research and Development Services
- Clinical Trials: Participation in and support of clinical trials focusing on expanding the use of TMS technology for various neuropsychiatric disorders beyond MDD, such as anxiety disorders, PTSD, and OCD.
- Innovation Pipeline: Ongoing research initiatives aimed at developing new TMS applications and enhancements to existing technologies.
Summary
Neuronetics Inc. is dedicated to advancing the treatment landscape for major depressive disorder and other mental health conditions through its pioneering TMS technology. By facilitating effective, non-invasive therapy options, providing comprehensive training and support for healthcare providers, and staying committed to research and innovation, Neuronetics plays a vital role in enhancing mental health care options for patients in need.
1. Segments
Neuronetics primarily operates in the following segments:
- Healthcare Providers: This includes hospitals, outpatient clinics, and mental health facilities that utilize Neuronetics technologies to treat patients with depression and other mood disorders.
- Patients: Individuals suffering from Major Depressive Disorder (MDD) and other related conditions who seek alternative treatment options often overlooked or inadequately addressed by traditional therapies.
- Research Institutions: Collaborates with academic and clinical research organizations to explore new applications of TMS and contribute to the body of scientific knowledge regarding neurological treatments.
Products
Neuronetics’ product lineup is centered around its TMS therapy systems. The most prominent products include:
a. NeuroStar TMS Therapy System
- Overview: This is the flagship product and the first FDA-cleared TMS system for the treatment of MDD in adults who have failed to respond to previous antidepressant medications.
- Technology: Employs magnetic fields to stimulate nerve cells in the brain, which is believed to help improve symptoms of depression.
- Features:
- Non-invasive and well-tolerated with favorable side effect profiles compared to traditional medications.
- Offers a personalized treatment protocol tailored to each patient’s specific needs.
- Provides real-time data for monitoring treatment progress and outcomes.
Services
In addition to its products, Neuronetics offers several services aimed at facilitating the adoption and effective use of its TMS technology:
a. Training and Education
- Provider Training: Comprehensive training programs for healthcare providers on operating the NeuroStar system and delivering TMS therapy safely and effectively.
- Patient Education: Resources and support for patients to better understand TMS therapy, including its benefits, process, and potential outcomes.
b. Clinical Support
- Consultative Services: Offering expertise and guidance to healthcare facilities on how to integrate TMS therapy into their existing treatment protocols.
- Clinical Data Collection: Support in gathering and analyzing clinical outcomes data to enhance treatment effectiveness and establish best practices in the deployment of TMS therapy.
c. Patient Support
- Access Programs: Resources for patients to understand insurance coverage and financial assistance options for those in need of TMS therapy.
- Follow-Up Care: Continuous engagement with patients post-treatment to assess ongoing mental health and satisfaction with TMS therapy.
d. Research and Development Services
- Clinical Trials: Participation in and support of clinical trials focusing on expanding the use of TMS technology for various neuropsychiatric disorders beyond MDD, such as anxiety disorders, PTSD, and OCD.
- Innovation Pipeline: Ongoing research initiatives aimed at developing new TMS applications and enhancements to existing technologies.
Summary
Neuronetics Inc. is dedicated to advancing the treatment landscape for major depressive disorder and other mental health conditions through its pioneering TMS technology. By facilitating effective, non-invasive therapy options, providing comprehensive training and support for healthcare providers, and staying committed to research and innovation, Neuronetics plays a vital role in enhancing mental health care options for patients in need.